Qiutang (Jennifer) Li

Company: Neurophth Therapeutics

Job title: Chief Scientific Officer

Seminars:

Advancing Gene Therapy for Mitochondrial Eye Diseases: LHON and ADOA 2:15 pm

Diving into the world of gene therapy and developing advanced gene therapy drugs for LHON (Leber’s Hereditary Optic Neuropathy) caused by ND4 and ND1 mutations, offering new hope for patients Exploring the progress of Neurophth’s NFS-01 gene therapy, currently in clinical stages, designed to target and treat LHON associated with ND4 mutations Discovering IND enabling…Read more

day: Day One